First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307 [0.03%]
替雷利珠单抗联合化疗用于晚期或转移性鳞状非小细胞肺癌一线治疗：RATIONALE-307研究的四年长期随访数据
Zhijie Wang,Xinmin Yu,Jun Zhao et al.
Zhijie Wang et al.
Introduction: Squamous nonsmall cell lung cancer (sq-NSCLC) is challenging to treat, with shorter survival when compared with other NSCLC subtypes. Tislelizumab has demonstrated efficacy when combined with chemotherapy fo...
Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO) [0.03%]
急性髓系白血病患者中FLT3突变的获得和丢失：一项非干预性队列研究（CLEVO）
Cristina Papayannidis,Irina Amitai,Pascal Turlure et al.
Cristina Papayannidis et al.
Introduction: FMS-like tyrosine kinase 3 (FLT3) mutations show variable detectability in relapse/refractory acute myeloid leukemia (AML) with unclear clonal evolution dynamics. ...
A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas [0.03%]
一项针对布鲁顿酪氨酸激酶抑制剂单药治疗B细胞淋巴瘤的反应率的 meta 分析研究
Pier Luigi Zinzani,Rhys Williams,Mei Xue et al.
Pier Luigi Zinzani et al.
Introduction: Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B cell lymphomas; however, evidence on their comparative efficacy remains limited. This meta-analysis compared the effi...
Exploring Patient Perspectives on Upper Tract Urothelial Cancer: A Qualitative Interview Study [0.03%]
上尿路尿路上皮癌患者视角探索性研究：定性访谈研究
Dina Filipenko,Michael Acquadro,Ola Ghatnekar et al.
Dina Filipenko et al.
Introduction: Patient interview data exploring the experiences of the most relevant symptoms and impacts of upper tract urothelial cancer (UTUC) remain scarce. This study aimed to develop a conceptual disease model (CDM) ...
Summary of Research: Elranatamab Fixed Dosing-A Safe, Effective, and Convenient Dosing Approach [0.03%]
Elranatamab 固定剂量方案：安全、有效且便捷的给药方式
Mohamed Elmeliegy,Pooneh Soltantabar,Jennifer Hibma et al.
Mohamed Elmeliegy et al.
This is a summary of the original research article "Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach". Understanding how body weight affects the safety and efficacy of a treatment is important to ensure optimal tr...
A Response to: Letter to the Editor Regarding "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain" [0.03%]
关于“Elranatamab与当前疗法在西班牙治疗三线暴露、复发和难治性多发性骨髓瘤（包括其他双特异性药物和医生选择的治疗方案）的成本效益”的信件回复
Virginia Lozano,Julia Llinares,Patrick Halavacek et al.
Virginia Lozano et al.
Letter to the Editor Regarding: "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain" [0.03%]
关于文章“Elranatamab与当前疗法在治疗三线暴露、复发和难治性多发性骨髓瘤（包括其他双特异性药物和西班牙医生选择的治疗）中的成本效益”的读者来信
Kirsten J M van Nimwegen,Mustafa Oguz,Raúl Morano et al.
Kirsten J M van Nimwegen et al.
Several Considerations on the Pathology, Treatment, and Prognosis of Laryngeal NUT Carcinoma [0.03%]
谈NUT型喉癌的病理、诊治及预后几项考虑
Andrés Coca-Pelaz,Alfio Ferlito
Andrés Coca-Pelaz
Laryngeal NUT carcinoma (NC) is an exceptionally rare and highly aggressive malignancy defined by rearrangements of the NUTM1 gene, most commonly involving BRD4. Owing to its morphologic overlap with poorly differentiated squamous cell carc...
Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil [0.03%]
维纳妥拉联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病：巴西可用药物的系统评价和网状 meta 分析
Bruno M Barros,Márcia Gisele S Costa,Marcelo G Correia et al.
Bruno M Barros et al.
Introduction: Venetoclax represents a significant advancement in target anticancer therapy in the management of relapsed/refractory chronic lymphocytic leukemia (RR-CLL). This study aims to compare the efficacy and safety...
Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab [0.03%]
顺铂不合格的肌层浸润性膀胱癌的新辅助治疗：TAR-200和恩沃单抗联合帕博利珠单抗时代的新进展、挑战与未来方向
Giuseppe Di Lorenzo,Massimo Di Maio,Carlo Buonerba
Giuseppe Di Lorenzo
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy remains the standard of care for patients with nonmetastatic muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin. However, many patients cannot r...